Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Worse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new study has found. Bradley J. Monk, MD, presented this finding and other…
English